HRP20161614T1 - Terapijska sredstva za smanjenje razina paratiroidnog hormona - Google Patents
Terapijska sredstva za smanjenje razina paratiroidnog hormona Download PDFInfo
- Publication number
- HRP20161614T1 HRP20161614T1 HRP20161614TT HRP20161614T HRP20161614T1 HR P20161614 T1 HRP20161614 T1 HR P20161614T1 HR P20161614T T HRP20161614T T HR P20161614TT HR P20161614 T HRP20161614 T HR P20161614T HR P20161614 T1 HRP20161614 T1 HR P20161614T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- cysteine
- peptide
- compound
- arginine
- Prior art date
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 239000000199 parathyroid hormone Substances 0.000 title claims 2
- 229960001319 parathyroid hormone Drugs 0.000 title claims 2
- 229940124597 therapeutic agent Drugs 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 229930028154 D-arginine Natural products 0.000 claims 5
- 230000001268 conjugating effect Effects 0.000 claims 5
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical group OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
- 229930195711 D-Serine Chemical group 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Chemical group CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 2
- 229930195710 D‐cysteine Natural products 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- SNDPXSYFESPGGJ-SCSAIBSYSA-N D-2-aminopentanoic acid Chemical group CCC[C@@H](N)C(O)=O SNDPXSYFESPGGJ-SCSAIBSYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical group C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 1
- 125000000028 D-cysteine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(S[H])([H])[H] 0.000 claims 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical group OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims 1
- 229930195715 D-glutamine Chemical group 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical group CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- 229930182819 D-leucine Chemical group 0.000 claims 1
- LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical group CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 claims 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical group OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 1
- 229930182832 D-phenylalanine Chemical group 0.000 claims 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical group CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 1
- 229930182831 D-valine Chemical group 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- -1 cationic amino acid Chemical class 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229960000478 cinacalcet hydrochloride Drugs 0.000 claims 1
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000000121 hypercalcemic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (14)
1. Spoj, koji obuhvaća peptid i konjugirajuću skupinu, gdje peptid sadrži aminokiselinsku sekvencu formule:
[image]
gdje
X1 je D-cistein;
X2 je D-arginin, D-alanin, D-valin, D-leucin, D-fenilalanin, D-serin, D-glutamin, D-norleucin ili D-norvalin;
X3 je D-arginin;
X4 je D-arginin ili ne-kationska aminokiselina, gdje X4 nije glicin, prolin ili aminokiselina s bočnim kiselinskim lancem;
X5 je D-arginin;
X6 je D-alanin, D-glicin ili D-serin;
X7 je D-arginin;
gdje su barem dva od X2, X3 i X4 nezavisno kationska podjedinica; i gdje je peptid vezan na svom N-kraju disulfidnom vezom za konjugirajuću skupinu.
2. Spoj prema zahtjevu 1, gdje spoj obuhvaća Ac-crrarar-NH2 (SEQ ID NO:25) ili Ac-carrrar-NH2 (SEQ ID NO:26).
3. Spoj prema zahtjevu 1, gdje peptid po duljini ima 8 do 11, 8 do 10 ili 8 do 9 aminokiselina.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, gdje se konjugirajuća skupina odabire između L-cisteina, D-cisteina, homocisteina, glutationa, pegiliranog cisteina ili polipeptida sa cisteinskim ostatkom.
5. Spoj prema zahtjevu 4, gdje je konjugirajuća skupina cistein pri čemu je cistein N-acetilirani cistein.
6. Spoj prema zahtjevu 4 ili 5, gdje polipeptid sa cisteinskim ostatkom ima jednaku sekvencu kao peptid.
7. Spoj prema zahtjevu 6, gdje spoj obuhvaća:
[image]
ili
[image]
8. Spoj koji se sastoji od peptida koji obuhvaća sekvencu carrrar (SEQ ID NO:2) i konjugirajuće skupine, taj peptid je povezan disulfidnom vezom.
9. Spoj prema zahtjevu 8, gdje je peptid kemijski modificiran na N-kraju, C-kraju ili na oba.
10. Spoj prema zahtjevu 8 ili zahtjevu 9, gdje je spoj Ac-c(C)arrrar-NH2 (SEQ ID NO:3).
11. Spoj prema bilo kojem od zahtjeva 1-5, gdje je spoj Ac-c(C)rrarar-NH2 (SEQ ID NO:28).
12. Pripravak koji sadrži spoj prema bilo kojem od zahtjeva 1 do 11, za uporabu u liječenju subjekta koji pati od sekundarnog hiperparatiroidizma (SHPT) ili hiperkalcemičnog poremećaja.
13. Pripravak koji sadrži spoj prema bilo kojem od zahtjeva 1 do 11, za uporabu u smanjivanju razina paratiroidnog hormona u subjekta.
14. Pripravak prema zahtjevu 12 ili 13, dalje sadrži drugo terapijsko sredstvo koje je vitamin D, analog vitamina D ili sinakalcet hidroklorid.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22969509P | 2009-07-29 | 2009-07-29 | |
| US25581609P | 2009-10-28 | 2009-10-28 | |
| US31363510P | 2010-03-12 | 2010-03-12 | |
| EP10805078.2A EP2459208B1 (en) | 2009-07-29 | 2010-07-29 | Therapeutic agents for reducing parathyroid hormone levels |
| PCT/US2010/043792 WO2011014707A2 (en) | 2009-07-29 | 2010-07-29 | Therapeutic agents for reducing parathyroid hormone levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161614T1 true HRP20161614T1 (hr) | 2017-02-24 |
Family
ID=43527590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161614TT HRP20161614T1 (hr) | 2009-07-29 | 2016-12-01 | Terapijska sredstva za smanjenje razina paratiroidnog hormona |
| HRP20190923TT HRP20190923T1 (hr) | 2009-07-29 | 2019-05-17 | Terapijska sredstva za smanjenje razina paratirodnog hormona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190923TT HRP20190923T1 (hr) | 2009-07-29 | 2019-05-17 | Terapijska sredstva za smanjenje razina paratirodnog hormona |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US8999932B2 (hr) |
| EP (5) | EP4154900A1 (hr) |
| JP (3) | JP5270799B2 (hr) |
| KR (1) | KR101781841B1 (hr) |
| CN (2) | CN107674114B (hr) |
| AU (1) | AU2010278897B2 (hr) |
| BR (1) | BR112012002143B8 (hr) |
| CA (1) | CA2769525C (hr) |
| CY (3) | CY1118388T1 (hr) |
| DK (2) | DK2459208T3 (hr) |
| ES (2) | ES2607954T3 (hr) |
| FR (1) | FR17C1009I2 (hr) |
| HK (1) | HK1167108A1 (hr) |
| HR (2) | HRP20161614T1 (hr) |
| HU (3) | HUE030960T2 (hr) |
| IL (1) | IL217749A (hr) |
| LT (3) | LT3192520T (hr) |
| LU (1) | LUC00008I2 (hr) |
| MX (1) | MX2012001213A (hr) |
| NO (1) | NO2017021I1 (hr) |
| NZ (1) | NZ597922A (hr) |
| PL (2) | PL2459208T3 (hr) |
| PT (2) | PT3192520T (hr) |
| RU (1) | RU2557654C3 (hr) |
| SG (2) | SG10201406921SA (hr) |
| SI (2) | SI2459208T1 (hr) |
| SM (1) | SMT201700014B (hr) |
| TW (1) | TWI520744B (hr) |
| WO (1) | WO2011014707A2 (hr) |
| ZA (1) | ZA201200726B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5645408B2 (ja) * | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| ES2607954T3 (es) | 2009-07-29 | 2017-04-04 | Kai Pharmaceuticals, Inc. | Agentes terapéuticos para reducir los niveles de hormona paratiroidea |
| WO2011108724A1 (ja) | 2010-03-04 | 2011-09-09 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| ES2712048T3 (es) | 2010-03-04 | 2019-05-09 | Ea Pharma Co Ltd | Derivado de alquilamina |
| EP2551262A4 (en) | 2010-03-24 | 2014-01-15 | Ajinomoto Kk | GLUTAMATE DERIVATIVES OR SALTS THEREOF |
| EP2554165A4 (en) | 2010-04-02 | 2014-04-30 | Ajinomoto Kk | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY |
| LT2717896T (lt) * | 2011-06-08 | 2017-02-27 | Kai Pharmaceuticals, Inc. | Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui |
| MX355063B (es) * | 2011-11-10 | 2018-04-04 | Kai Pharmaceuticals Inc | Calcimiméticos y métodos para su uso. |
| CA2870711A1 (en) | 2012-04-17 | 2013-10-24 | Brown University | Neuroprotective composition and method of use |
| US20200354428A9 (en) | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
| EP3013318B1 (en) * | 2013-06-28 | 2017-04-19 | Amgen Inc. | Stable liquid formulation of amg 416 (velcalcetide) |
| HUE048489T2 (hu) | 2014-04-03 | 2020-07-28 | Amgen Inc | Eljárás AMG 416 elõállítására |
| CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| CA2980960A1 (en) | 2015-03-26 | 2016-09-29 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| US9336841B1 (en) * | 2015-04-16 | 2016-05-10 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipeline register with data alignment therein |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| US10105375B2 (en) | 2016-08-30 | 2018-10-23 | Wisconsin Alumni Research Foundation | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism |
| JP2021501793A (ja) * | 2017-11-07 | 2021-01-21 | アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ | 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法 |
| JP6510136B1 (ja) | 2017-12-20 | 2019-05-08 | Ｅａファーマ株式会社 | 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物 |
| WO2020093069A1 (en) * | 2018-11-02 | 2020-05-07 | Ampersand Biopharmaceuticals, Inc. | Management of risk of cation overload and electrolyte imbalance with topically applied buffers |
| WO2020204117A1 (ja) | 2019-04-03 | 2020-10-08 | Ｅａファーマ株式会社 | 安定性の良好な医薬組成物 |
| TW202122410A (zh) * | 2019-12-09 | 2021-06-16 | 大陸商北京拓界生物醫藥科技有限公司 | 鈣敏感受體激動劑化合物及其應用 |
| US20230223125A1 (en) * | 2020-05-04 | 2023-07-13 | University Of Louisville Research Foundation, Inc. | Artificial intelligence-based systems and methods for dosing of pharmacologic agents |
| JP7440132B2 (ja) * | 2020-09-10 | 2024-02-28 | シャンシー・ミコ・テクノロジー・カンパニー・リミテッド | 二重特異性融合ポリペプチド化合物 |
| US11359134B2 (en) | 2020-10-19 | 2022-06-14 | Saudi Arabian Oil Company | Treatment fluids and methods for recovering hydrocarbons from a subterranean formation |
| WO2022257958A1 (zh) * | 2021-06-08 | 2022-12-15 | 北京拓界生物医药科技有限公司 | 一种钙敏感受体激动剂的组合物及其应用 |
| WO2022257940A1 (zh) * | 2021-06-08 | 2022-12-15 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| AU9131091A (en) * | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| EP0917537B1 (en) | 1996-07-31 | 2005-09-07 | The General Hospital Corporation | Novel parathyroid hormone-related peptide analogs |
| US5895368A (en) | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| WO1998017299A1 (en) | 1996-10-18 | 1998-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase c, methods and compositions |
| US5955431A (en) * | 1997-02-05 | 1999-09-21 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
| KR100351213B1 (ko) | 1997-05-14 | 2002-09-05 | 아벤티스 파마슈티칼스 인크. | 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 |
| ATE251913T1 (de) * | 1997-05-21 | 2003-11-15 | Univ Leland Stanford Junior | Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| JP2000336099A (ja) * | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US20020068342A1 (en) * | 2000-02-09 | 2002-06-06 | Rami Khosravi | Novel nucleic acid and amino acid sequences and novel variants of alternative splicing |
| WO2002006218A2 (en) | 2000-07-18 | 2002-01-24 | Bone Care International, Inc. | STABILIZED 1α-HYDROXY VITAMIN D |
| DE10041126A1 (de) * | 2000-08-22 | 2002-04-04 | Aventis Res & Tech Gmbh & Co | DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| JP4115838B2 (ja) | 2001-01-18 | 2008-07-09 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | δＰＫＣの活性化および阻害のためのペプチド |
| AU2002240312A1 (en) | 2001-02-08 | 2002-08-19 | Pankaj Paranjp | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| US20030036627A1 (en) | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| JP4310106B2 (ja) | 2001-02-23 | 2009-08-05 | ポリファー リミテッド | 抗菌活性を有するテンプレート結合ペプチド擬似体 |
| WO2003014078A2 (en) * | 2001-08-08 | 2003-02-20 | The Research Foundation Of The State University Of New York | Muc7d1 peptides as antifungal and antibacterial agents |
| US6998404B2 (en) | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| US7060023B2 (en) | 2001-09-25 | 2006-06-13 | The Foundry Inc. | Pericardium reinforcing devices and methods of using them |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| US20040018976A1 (en) | 2002-05-14 | 2004-01-29 | Feder John N. | Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof |
| CA2543072A1 (en) | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| CA2549052A1 (en) | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| JP2008508294A (ja) * | 2004-07-27 | 2008-03-21 | ジェンザイム・コーポレイション | 骨の再生のためのチロトロピンの使用法 |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| KR100687932B1 (ko) * | 2005-08-09 | 2007-02-27 | 삼성전자주식회사 | 영상표시장치 및 영상표시방법 |
| US20070066514A1 (en) * | 2005-08-30 | 2007-03-22 | Acologix, Inc. | Regulation of mineral and skeletal metabolism |
| JP5645408B2 (ja) * | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| JP2010516707A (ja) | 2007-01-19 | 2010-05-20 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| EP2197495A2 (en) * | 2007-10-02 | 2010-06-23 | MDRNA, Inc. | Lipopeptides for delivery of nucleic acids |
| WO2009075773A2 (en) | 2007-12-07 | 2009-06-18 | Goldstein Steven A | Identification of toxin ligands |
| US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| ES2607954T3 (es) | 2009-07-29 | 2017-04-04 | Kai Pharmaceuticals, Inc. | Agentes terapéuticos para reducir los niveles de hormona paratiroidea |
| LT2717896T (lt) | 2011-06-08 | 2017-02-27 | Kai Pharmaceuticals, Inc. | Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui |
| MX355063B (es) | 2011-11-10 | 2018-04-04 | Kai Pharmaceuticals Inc | Calcimiméticos y métodos para su uso. |
-
2010
- 2010-07-29 ES ES10805078.2T patent/ES2607954T3/es active Active
- 2010-07-29 JP JP2012523061A patent/JP5270799B2/ja active Active
- 2010-07-29 SM SM201700014T patent/SMT201700014B/it unknown
- 2010-07-29 CA CA2769525A patent/CA2769525C/en active Active
- 2010-07-29 SG SG10201406921SA patent/SG10201406921SA/en unknown
- 2010-07-29 EP EP22193946.5A patent/EP4154900A1/en active Pending
- 2010-07-29 TW TW099125105A patent/TWI520744B/zh active
- 2010-07-29 EP EP19159337.5A patent/EP3539555B1/en active Active
- 2010-07-29 PL PL10805078T patent/PL2459208T3/pl unknown
- 2010-07-29 EP EP10805078.2A patent/EP2459208B1/en active Active
- 2010-07-29 EP EP20209086.6A patent/EP3808363B1/en active Active
- 2010-07-29 LT LTEP16190682.1T patent/LT3192520T/lt unknown
- 2010-07-29 SG SG2012006185A patent/SG178143A1/en unknown
- 2010-07-29 HU HUE10805078A patent/HUE030960T2/en unknown
- 2010-07-29 CN CN201710873189.9A patent/CN107674114B/zh active Active
- 2010-07-29 MX MX2012001213A patent/MX2012001213A/es active IP Right Grant
- 2010-07-29 PT PT16190682T patent/PT3192520T/pt unknown
- 2010-07-29 KR KR1020127004785A patent/KR101781841B1/ko active IP Right Grant
- 2010-07-29 LT LTEP10805078.2T patent/LT2459208T/lt unknown
- 2010-07-29 PT PT108050782T patent/PT2459208T/pt unknown
- 2010-07-29 PL PL16190682T patent/PL3192520T3/pl unknown
- 2010-07-29 SI SI201031337A patent/SI2459208T1/sl unknown
- 2010-07-29 NZ NZ597922A patent/NZ597922A/en unknown
- 2010-07-29 BR BR112012002143A patent/BR112012002143B8/pt active IP Right Grant
- 2010-07-29 WO PCT/US2010/043792 patent/WO2011014707A2/en active Application Filing
- 2010-07-29 SI SI201031894T patent/SI3192520T1/sl unknown
- 2010-07-29 EP EP16190682.1A patent/EP3192520B1/en active Active
- 2010-07-29 DK DK10805078.2T patent/DK2459208T3/en active
- 2010-07-29 CN CN201080045024.9A patent/CN102711789B/zh active Active
- 2010-07-29 RU RU2012107428A patent/RU2557654C3/ru active
- 2010-07-29 DK DK16190682.1T patent/DK3192520T3/da active
- 2010-07-29 US US12/846,724 patent/US8999932B2/en active Active
- 2010-07-29 AU AU2010278897A patent/AU2010278897B2/en active Active
- 2010-07-29 HU HUE16190682A patent/HUE043838T2/hu unknown
- 2010-07-29 ES ES16190682T patent/ES2729051T3/es active Active
-
2012
- 2012-01-26 IL IL217749A patent/IL217749A/en active Protection Beyond IP Right Term
- 2012-01-30 ZA ZA2012/00726A patent/ZA201200726B/en unknown
- 2012-02-02 US US13/365,213 patent/US8377880B2/en active Active
- 2012-08-14 HK HK12107946.6A patent/HK1167108A1/zh unknown
-
2013
- 2013-02-18 US US13/769,744 patent/US9278995B2/en active Active
- 2013-05-09 JP JP2013099331A patent/JP5764613B2/ja active Active
-
2014
- 2014-02-10 JP JP2014023488A patent/JP2014094967A/ja active Pending
-
2015
- 2015-03-04 US US14/639,020 patent/US9567370B2/en active Active
-
2016
- 2016-02-08 US US15/018,567 patent/US9701712B2/en active Active
- 2016-12-01 HR HRP20161614TT patent/HRP20161614T1/hr unknown
- 2016-12-27 CY CY20161101349T patent/CY1118388T1/el unknown
-
2017
- 2017-01-09 US US15/402,133 patent/US20170114095A1/en not_active Abandoned
- 2017-03-01 HU HUS1700008 patent/HUS1700008I1/hu unknown
- 2017-03-09 LU LU00008C patent/LUC00008I2/fr unknown
- 2017-03-10 LT LTPA2017007C patent/LTC2459208I2/lt unknown
- 2017-03-16 CY CY2017010C patent/CY2017010I1/el unknown
- 2017-03-17 FR FR17C1009C patent/FR17C1009I2/fr active Active
- 2017-05-05 NO NO2017021C patent/NO2017021I1/no unknown
- 2017-06-21 US US15/629,536 patent/US10280198B2/en active Active
-
2019
- 2019-03-11 US US16/298,902 patent/US20190194252A1/en not_active Abandoned
- 2019-05-17 HR HRP20190923TT patent/HRP20190923T1/hr unknown
- 2019-05-31 CY CY20191100579T patent/CY1121922T1/el unknown
-
2020
- 2020-09-02 US US17/010,773 patent/US20200399309A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/960,060 patent/US20240116983A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161614T1 (hr) | Terapijska sredstva za smanjenje razina paratiroidnog hormona | |
| JP2013500990A5 (hr) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| MX2009007008A (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo. | |
| WO2009009727A3 (en) | Ghrh analogs and therapeutic uses thereof | |
| IL180727A0 (en) | Antimicrobial peptides comprising an arginine and/or lysine -containing motif | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| JP2014224126A5 (hr) | ||
| PE20120021A1 (es) | Mutantes fgf21 | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| CA2651990C (en) | Improved antimicrobial peptides | |
| CL2012001685A1 (es) | Análogo peptídico de oxintomodulina, en donde el aminoácido c-terminal es opcionalmente amidado; composición farmacéutica que lo comprende; y su uso en la preparación de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad. | |
| WO2004103390A3 (en) | Stable analogs of peptide and polypeptide therapeutics | |
| WO2009046220A3 (en) | Lipopeptides for delivery of nucleic acids | |
| IN2014CN02050A (hr) | ||
| HRP20191965T1 (hr) | Stabilizirani polipeptidi faktora rasta slični inzulinu | |
| WO2008057463A3 (en) | Peptide-based conditioners | |
| WO2006087550A8 (en) | Amyloid-binding peptides, analogues and uses thereof | |
| JP2004537581A5 (hr) | ||
| MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| EA201390998A1 (ru) | Препарат фторуглеродсвязанных пептидов | |
| WO2008093058A3 (en) | Peptides and their use | |
| EA201100459A1 (ru) | Композиции, включающие интерлейкин-1 и пептиды | |
| WO2006075253A3 (en) | Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides. |